Facebook
X
LinkedIn
Forward
Updates in the Role of Durvalumab in Limited-Stage Small Cell Lung Cancer
- The OPN and the ACCP H/O PRN Journal Club is a monthly virtual (online) event.
Overview
Prior to the ADRIATIC trial, the treatment landscape for limited-stage small cell lung cancer remained unchanged for several decades. The ADRIATIC trial was pivotal to the approval and updated guidance for use of durvalumab in the setting of limited-stage small cell lung cancer. This presentation will focus on reviewing the ADRIATIC trial, including its design, patient population, intervention, and key findings. It will also provide a brief overview of the limited-stage small cell lung cancer and summarize available FDA-approved treatments. Finally, we will discuss the role of durvalumab in clinical practice and impact in care for this patient population.
Identified Gap(s)
Oncology pharmacists lack regular, structured opportunities to engage with emerging literature and apply new evidence to clinical practice. The rapid pace of drug development, evolving treatment guidelines, and increasing complexity of oncology care demand ongoing education that is interactive and peer driven. The absence of oncology-specific journal clubs limits pharmacists’ ability to stay current, critically evaluate research, and contribute fully to multidisciplinary care—ultimately impacting patient outcomes.
Description of Current State
Oncology pharmacists are increasingly stepping into high-value, patient-focused roles due to the growing complexity of cancer care and shortages of oncologists and nurses. With over 50 new cancer drugs approved in 2024 alone, the need for pharmacists to stay current with treatment advances is critical.1 However, educational gaps persist, as pharmacists often lack access to oncology-focused continuing education. As drug experts on the care team, they must be equipped to manage complex therapies and fill care gaps—particularly in areas like pregnancy-associated cancer and supportive care.
Description of desired/achievable state
Oncology pharmacists will have access to a virtual, accredited journal club designed to support continuous learning and clinical application of emerging evidence. This interactive platform will foster peer-to-peer discussion, enhance critical literature appraisal skills, and empower pharmacists to deliver evidence-based care in complex scenarios, ultimately strengthening their role within the oncology care team.
Upon completion of this journal club, you will:
- Summarize the current treatment landscape for limited-stage small cell lung cancer
- Discuss the ADRIATIC trial and the role of durvalumab in limited-stage small cell lung cancer after chemoradiotherapy
Target Audience
This activity is intended for oncology pharmacists, pharmacy techs, and pharmacy residents who are involved in the treatment of cancer patients.
Presented By
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Eastern Standard Time Zone
Thursday, August 21, 2025 | |
| 3:00pm | Welcome and Introduction » Olivia White, PharmD - Hematology/Oncology Pharmacy Specialist at the University of Texas Southwestern Medical Center |
| 3:05pm | Updates in the Role of Durvalumab in Limited-Stage Small Cell Lung Cancer » Filzah Shafiq, PharmD - Arnold & Marie Schwartz College of Pharmacy and Health Sciences |
| 3:35pm | Closing Comments » Olivia White, PharmD - Hematology/Oncology Pharmacy Specialist at the University of Texas Southwestern Medical Center |
Faculty
Olivia White, PharmD, BCOP (Moderator)
Hematology/Oncology Pharmacy Specialist
University of Texas Southwestern Medical Center
Dallas, TX
Dr. Olivia White is a Hematology/Oncology Pharmacy Specialist at the University of Texas Southwestern Medical Center. She completed her pharmacy school at University of Kentucky in 2021, followed by a 2-year residency program specializing in Hematology and Oncology at Duke University Hospital. Her areas of interest include malignant hematology management, cardio-oncology, pharmacoequity, and expanding the role of the pharmacist in hematology/oncology practice.
Filzah Shafiq, PharmD (Speaker)
PharmD Candidate 2027
Arnold & Marie Schwartz College of Pharmacy and Health Sciences
Long Island University
Brooklyn, NY
Program Planners
Shawn Griffin
Oncology Pharmacist/Assistant Clinical Professor
University of California, Irvine
Irvine, California
Shawn Griffin is a Board Certified Oncology Pharmacist and Health Sciences Assistant Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He practices within the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center. Prior to joining UCI, Griffin worked as a Hematology/Stem Cell Transplant pharmacist at Indiana University Health for five years. He received PharmD from the UNC Eshelman School of Pharmacy and completed a PGY1 Pharmacy and PGY2 Oncology Pharmacy Residency at the University of Florida Health Shands Hospital.
Kyle Zachoiski, PharmD, BCOP (Planner)
Clinical Pharmacy Specialist,
Hematology & Oncology
Virginia Commonwealth University Health System
Richmond, VA
Dr. Kyle Zacholski is a board-certified oncology pharmacist at VCU Health and clinical assistant professor at VCU School of Pharmacy in Richmond, VA. At VCU Health, he serves as the program director for the PGY2 Oncology Pharmacy Residency program and specializes in malignant hematology with over 5 years of clinical practice experience. His research interests include optimizing treatment and supportive care for patients with acute leukemia and bone marrow failure syndromes. Dr. Zacholski also currently serves as a pharmacy committee member for the Alliance for Clinical Trials in Oncology cooperative group.
Disclosures
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
Planners
*Horizon CME has mitigated and resolved all relevant financial relationships
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Available Credit
- 0.50 ACPE PharmacyThe Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 0.50 credit by the Washington State Pharmacy Association.
This activity is approved for up to 0.50 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Thu, 08/21/2025 - 11:55am-Thu, 08/21/2025 - 12:35pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 60 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
How to obtain credit for attendance (eligibility requirement and process for obtaining certificate)
To receive documentation of credit, participants must:
Login to the educational portal
Attend the educational activity
Complete the online evaluation form. The last day to access the evaluation is September 22, 2025 at 11:59pm PST*
Attest to the number of hours in attendance in order to generate your certificate
*Requests from learners to claim credit after the evaluation closes will not be granted